Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
US and EU compete on regulatory vigor; former chiefs seek elevation of status for FDA
This week, Phispers reports on Sanofi and Boehringer Ingelheim’s asset swap, a possible cure f
